Frequency of detection and burden of somatic mutations other than ABL1 KD mutations increase in cases of TKI-non response and, more prominently, with progression to advanced phases of CML, contributing to the disease transformation itself [132,133]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.